Preissner K T, Grulich-Henn J, Ehrlich H J, Declerck P, Justus C, Collen D, Pannekoek H, Müller-Berghaus G
Clinical Research Unit for Blood Coagulation and Thrombosis, Max-Planck-Gesellschaft, Giessen, West Germany.
J Biol Chem. 1990 Oct 25;265(30):18490-8.
The interaction of plasminogen activator inhibitor-1 (PAI-1) with its binding protein vitronectin (VN) (Declerck, P. J., De Mol, M., Alessi, M.-C., Baudner, S., Paques, E.-P., Preissner, K. T., Müller-Berghaus, G., and Collen, D. (1988) J. Biol. Chem. 263, 15454-15461) in the extracellular matrix (ECM) of cultured human endothelial cells (HUVEC) was studied. Like PAI-1, VN was found associated with the ECM as evidenced by direct antibody binding, by Western blot analysis as well as by diffuse immunofluorescence staining in permeabilized HUVEC. The specific interaction of VN with confluent monolayers of HUVEC was found to be saturable within 2-4 h at 37 degrees C only with respect to binding to the cells, while no saturable binding to the underlying ECM was observed, indicating that the majority if not all ECM-associated VN was derived from the culture medium. In contrast to PAI-1, ECM-associated VN was resistant toward glycine (pH 2.3), guanidine or urokinase treatment, suggesting that VN was tightly associated with the ECM network. Binding of recombinant PAI-1 (rPAI-1) was largely blocked by anti-VN IgG and only partly by anti-collagen IgG but not by antibodies against other ECM components, indicating that VN constitutes the primary binding protein for ECM-associated PAI-1. This contention was supported by ligand blotting experiments in which rPAI-1 was reacted with nitrocellulose replicas of electrophoretically separated ECM components. Protein band(s) (Mr = 63,000-67,000), comigrating with bovine VN (i.e. medium-derived VN) rather than with human VN were identified as major binding component(s). Moreover, binding studies with purified components revealed that PAI-1 did not show any affinity for collagen (type I/III) alone, whereas VN collagen coating was a much better template for PAI-1 binding than VN alone and that conformationally extended VN provides maximal PAI-1 binding capacity. Binding of rPAI-1 to surface-coated VN was saturable and revealed that (unlike urokinase) heparin or the synthetic peptide Gly-Arg-Gly-Asp-Ser did not inhibit PAI-1 binding. Ligand binding of rPAI-1 to nitrocellulose replicas from sodium dodecyl sulfate-polyacrylamide gels containing electrophoretically separated peptides from VN digests documented the association of PAI-1 with Mr = 10,000-20,000 fragments originating from the heparin-binding domain of VN. These results indicate that the exposure of the glycosaminoglycan-binding domain in VN may allow the concomitant binding of PAI-1 and heparin-like molecules to this region of the VN molecule.(ABSTRACT TRUNCATED AT 400 WORDS)
研究了纤溶酶原激活物抑制剂 -1(PAI -1)与其结合蛋白玻连蛋白(VN)(德克莱克,P. J.,德莫尔,M.,阿莱西,M.-C.,鲍德纳,S.,帕克斯,E.-P.,普赖斯纳,K. T.,米勒 - 伯格豪斯,G.,和科伦,D.(1988)《生物化学杂志》263,15454 - 15461)在培养的人内皮细胞(HUVEC)细胞外基质(ECM)中的相互作用。与PAI -1一样,通过直接抗体结合、蛋白质印迹分析以及通透化的HUVEC中的弥漫性免疫荧光染色证明,VN与ECM相关联。发现VN与汇合的HUVEC单层的特异性相互作用在37℃下2 - 4小时内仅就与细胞的结合而言是可饱和的,而未观察到与下层ECM的可饱和结合,这表明即使不是所有与ECM相关的VN,大部分也是来自培养基。与PAI -1不同,与ECM相关的VN对甘氨酸(pH 2.3)、胍或尿激酶处理具有抗性,这表明VN与ECM网络紧密相关。重组PAI -1(rPAI -1)的结合在很大程度上被抗VN IgG阻断,仅部分被抗胶原蛋白IgG阻断,但不被针对其他ECM成分的抗体阻断,这表明VN构成了与ECM相关的PAI -1的主要结合蛋白。配体印迹实验支持了这一观点,其中rPAI -1与电泳分离的ECM成分的硝酸纤维素复制品反应。鉴定出与牛VN(即培养基来源的VN)而非人VN共迁移的蛋白带(Mr = 63,000 - 67,000)为主要结合成分。此外,用纯化成分进行的结合研究表明,PAI -1单独对胶原蛋白(I/III型)没有任何亲和力,而VN胶原蛋白包被比单独的VN是更好的PAI -1结合模板,并且构象伸展的VN提供最大的PAI -1结合能力。rPAI -1与表面包被的VN的结合是可饱和的,并且表明(与尿激酶不同)肝素或合成肽甘氨酸 - 精氨酸 - 甘氨酸 - 天冬氨酸 - 丝氨酸不抑制PAI -1结合。rPAI -1与来自十二烷基硫酸钠 - 聚丙烯酰胺凝胶的硝酸纤维素复制品的配体结合,该凝胶包含来自VN消化物的电泳分离肽,证明了PAI -1与源自VN肝素结合域的Mr = 10,000 - 20,000片段的关联。这些结果表明,VN中糖胺聚糖结合域的暴露可能允许PAI -1和类肝素分子同时结合到VN分子的该区域。(摘要截短至400字)